Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sernova Biotherapeutics Inc (TSV:SVA)

N/A UNCHANGED
Last Price Updated: 3:59 PM EDT, Jun 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sernova Biotherapeutics Inc

CanSino's Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?
Key Takeaways: CanSino’s Covid-19 vaccine Convidecia will be admitted to the global Covax program following its approval by the WHO The approval could have limited... 
Via Benzinga
SINOVAC Updates the Status Under Holding Foreign Companies Accountable Act
From Sinovac Biotech Ltd.
Via Business Wire
SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F
From Sinovac Biotech Ltd.
Via Business Wire
Sinovac Amends Shareholder Rights Plan
From Sinovac Biotech Ltd.
Via Business Wire
HFCAA News: 128 Chinese Stocks the SEC Could Delist
The SEC has released a massive list of Chinese stocks that could face delisting on Holding Foreign Companies Accountable Act news. 
Via InvestorPlace
New Energy Lands as Hottest Category Among Chinese Concept Stocks in 2021 – Bamboo Works Special Report
Investors kept a close look at China’s solar and wind power stocks last year, but were least interested in the hobbled education sector By Bamboo Works team Chinese concept... 
Via Benzinga
Pfizer, AstraZeneca or J&J COVID-19 Shots Boost Sinovac Regime, Brazilian Study Shows
A third booster dose of a COVID-19 vaccine from either AstraZeneca Plc (NASDAQ: AZN), Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX), or ... 
Via Benzinga
Sinovac's COVID-19 Vaccine With Pfizer Booster Less Effective Against Omicron: Reuters
China-based Sinovac Biotech Ltd's (NASDAQ: SVA) two-dose COVID-19 vaccine followed by a booster Pfizer Inc (NYSE: PFE) -BioNTech SE (NASDAQ: BNTX)... 
Via Benzinga
SINOVAC Reports Unaudited First Half of 2021 Financial Results
From Sinovac Biotech Ltd.
Via Business Wire
Antigua Court of Appeal Rules in Favor of SINOVAC, Upholds 2018 Judgment
From SINOVAC Biotech Ltd.
Via Business Wire
SINOVAC Beijing Settled Litigation of Its Business License and Seals
From SINOVAC Biotech Ltd.
Via Business Wire
Preliminary Results Show SINOVAC’s COVID-19 Vaccine Demonstrates Good Safety Profile Among the Pediatric and Adolescent Population
From SINOVAC Biotech Ltd.
Via Business Wire
Sinovac's COVID-19 Vaccine Shows Efficacy, But Lags Rivals In Malaysian Study: Reuters
According to a real-world study from Malaysia, Sinovac Biotech Ltd's (NASDAQ: SVA) COVID-19 vaccine, CoronaVac, showed effectiveness against serious illness. ... 
Via Benzinga
Week In Review: Sanofi Acquires Kadmon, A US-China Pharma, For $1.9 Billion
France's Sanofi will acquire Kadmon Holdings​​ of New York City in a $1.9 billion deal. In 2019, Kadmon formed a JV with BioNova Pharma to develop its novel lead drug, Rezurock (belumosudil) in China. 
Via Talk Markets
New Research on SINOVAC’s COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, Including the Delta Variant
From SINOVAC Biotech Ltd.
Via Business Wire
SINOVAC Announces COVID-19 Vaccine Approved for Emergency Use in Chile for Children and Adolescents
From SINOVAC Biotech Ltd.
Via Business Wire
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... 
Via Benzinga
Inovio To Start Global Late-Stage COVID-19 Vaccine Trial
The regulatory authority of Brazil has signed off Inovio Pharmaceuticals Inc's (NASDAQ: INO) global Phase 3 segment of its INNOVATE Phase 2/3 trial for INO-... 
Via Benzinga
SINOVAC Announces Positive Data on Booster Shots of CoronaVac®, Induces Strong Immune Response in Adult and Elderly Populations
From SINOVAC Biotech Ltd.
Via Business Wire
EMA Starts Rolling Review Of Glaxo - Sanofi COVID-19 Vaccine
EMA's human medicines committee has kicked off a rolling review of a COVID-19 vaccine from Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (... 
Via Benzinga
SINOVAC Receives Approval on Sabin Strain Based Inactivated Polio Vaccine (sIPV) to Support Global Polio Endgame Strategy
From SINOVAC Biotech Ltd.
Via Business Wire
Lancet Study Shows BioNTech COVID-19 Vaccine Generates 10X Higher Antibody Levels Compared to Sinovac Shot
A new Hong Kong study has found that people fully vaccinated with the BioNTech SE (NASDAQ: BNTX) COVID-19 shot have ten times higher antibody concentrations than those... 
Via Benzinga
SINOVAC Enters Into Agreement to Supply CoronaVac® to COVAX
From SINOVAC Biotech Ltd.
Via Business Wire
The Lancet Infectious Diseases Published Data from Sinovac’s Phase I/II Study, World’s First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3 to 17 Years Old
From Sinovac Biotech Ltd.
Via Business Wire
World Health Organization Authorizes SINOVAC’s CoronaVac® for Emergency Use
From SINOVAC Biotech Ltd.
Via Business Wire
Sanofi, Walvax COVID-19 Vaccine Phase 3 Trials to Commence in Mexico: Reuters
Mexico Foreign Minister Marcel Ebrard said that the country would begin phase 3 trials for COVID-19 vaccines by Sanofi SA (NASDAQ: SNY) and China's Walvax... 
Via Benzinga
Week In Review: WHO Close To Approving Global Use For Two China COVID-19 Vaccines
The World Health Organization approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the pandemic. Sinovac's inactivated COVID-19 vaccine... 
Via Talk Markets
Sinovac Reports Unaudited Fourth Quarter 2020 Financial Results and Files 2020 Annual Report on Form 20-F
From Sinovac Biotech Ltd.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.